福瑞股份收盘上涨4.50%，滚动市盈率122.20倍，总市值121.23亿元

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Furuya Co., which has a current PE ratio of 122.20, significantly higher than the industry average of 53.93 [1][2] - Furuya Co. has a total market capitalization of 12.123 billion yuan, ranking 109th in the medical device industry based on PE ratio [1][2] - The company experienced a net inflow of 8.6534 million yuan in main funds on August 6, but has seen a total outflow of 52.424 million yuan over the past five days [1] Group 2 - Furuya Co.'s main business includes the production and sales of drugs in the liver disease field, development and sales of diagnostic equipment, and related medical services, with its primary product being the compound tortoise shell soft liver tablets [1] - The latest quarterly report for Q1 2025 shows that the company achieved an operating income of 330 million yuan, a year-on-year increase of 2.35%, while net profit was 28.6367 million yuan, reflecting a year-on-year decrease of 32.97% [1] - The gross profit margin for Furuya Co. stands at 76.76% [1]